Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.44 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635413 | 0.87 | RECQL (0.45) | RECQLSMN1; SMN2MEN1KMT2APSMB5 | |
| SCHEMBL2635885 | 0.84 | KMT2A (0.47) | RECQLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2635632 | 0.84 | ALDH1A1 (0.50) | GPR34PKMSMN1; SMN2PYGLMEN1 | |
| SCHEMBL2635556 | 0.83 | RAB9A (0.59) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2635799 | 0.82 | POLB (0.47) | RECQLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2635529 | 0.81 | ALDH1A1 (0.56) | PKMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2635701 | 0.81 | MEN1 (0.60) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2635965 | 0.77 | TDP1 (0.51) | MEN1KMT2A | |
| SCHEMBL2636130 | 0.77 | POLB (0.49) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2635480 | 0.77 | TRPM4 (0.55) | SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | claimed |
| EP-2438037-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | claimed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | claimed |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| EP-2438037-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | GPR34 719/4885PKM 2447/4885RECQL 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.